Fennec Pharmaceuticals Inc (TSE:FRX) – Stock analysts at Wedbush issued their FY2024 earnings estimates for shares of Fennec Pharmaceuticals in a report released on Tuesday, February 11th. Wedbush analyst D. Nierengarten forecasts that the biopharmaceutical company will post earnings of $3.59 per share for the year.
Fennec Pharmaceuticals (TSE:FRX) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported C($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of C($0.31) by C$0.19.
FRX opened at C$10.34 on Thursday. The company has a market capitalization of $173.49 million and a price-to-earnings ratio of -16.92. Fennec Pharmaceuticals has a 1-year low of C$4.35 and a 1-year high of C$10.34. The business has a 50 day moving average price of C$8.48 and a two-hundred day moving average price of C$6.74.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
Recommended Story: Gross Domestic Product (GDP)
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.